Your browser doesn't support javascript.
loading
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.
Baeten, Dominique; Østergaard, Mikkel; Wei, James Cheng-Chung; Sieper, Joachim; Järvinen, Pentti; Tam, Lai-Shan; Salvarani, Carlo; Kim, Tae-Hwan; Solinger, Alan; Datsenko, Yakov; Pamulapati, Chandrasena; Visvanathan, Sudha; Hall, David B; Aslanyan, Stella; Scholl, Paul; Padula, Steven J.
Afiliación
  • Baeten D; Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands.
  • Østergaard M; Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark.
  • Wei JC; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Sieper J; Department of Internal Medicine, Institute of Medicine, Chung Shan Medical University, Chung Shan Medical University Hospital, Taichung, Taiwan.
  • Järvinen P; Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan.
  • Tam LS; Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Salvarani C; Kiljavan Lääketutkimus Oy, Hyvinkää, Finland.
  • Kim TH; Department of Medicine and Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
  • Solinger A; Rheumatology Unit, Azienda Ospedaliera-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Datsenko Y; Università di Modena e Reggio Emilia, Modena, Italy.
  • Pamulapati C; Department of Rheumatology, Hanyang University Hospital, Seoul, The Republic of Korea.
  • Visvanathan S; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA.
  • Hall DB; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
  • Aslanyan S; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA.
  • Scholl P; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA.
  • Padula SJ; Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA.
Ann Rheum Dis ; 77(9): 1295-1302, 2018 09.
Article en En | MEDLINE | ID: mdl-29945918
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Espondilitis Anquilosante / Antirreumáticos / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Rheum Dis Año: 2018 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Espondilitis Anquilosante / Antirreumáticos / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Rheum Dis Año: 2018 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido